BioPharmSignal logoBioPharmSignal

Biotech News

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Theravance Biopharma (TBPH)Theravance BiopharmaEarnings

Previously announced acquisition by Zymeworks expected to close in second half of 2026 YUPELRI ® Collaboration Revenue increased 11% year-over-year 1, from $18.7 million to $20.7 million, driven by continued Net Sales growth and improved operating leverage Organizational restructuring and cost

Related news

TBPHTheravance Biopharma2026-05-07 12:30 EST

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-03-19 12:30 EST

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

XAIRBeyond Air2026-08-13 11:00 EST

Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update

XAIRBeyond Air2026-06-26 11:00 EST

Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update

INSMInsmed2026-08-06 11:00 EST

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update

PULMPulmatrix2026-08-13 12:15 EST

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

RVPHReviva Pharmaceuticals2026-08-12 20:29 EST

Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights

SVRASavara, Inc.2018-11-07 21:02 EST

Savara Reports Third Quarter 2018 Financial Results and Provides Business Update

SVRASavara, Inc.2018-08-09 20:03 EST

Savara Reports Second Quarter 2018 Financial Results and Provides Positive Business Update

INSMInsmed2026-07-23 11:00 EST

Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026

View all latest news

Theravance Biopharma

Respiratory Medicines Theravance Biopharma is a biopharmaceutical company whose principal economic asset is a respiratory medicine commercialized through a collaboration. YUPELRI YUPELRI, or revefenacin, is a once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease....

Recent company news

TBPHTheravance Biopharma2026-08-10 12:30 EST

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-06-29 10:00 EST

THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT

TBPHTheravance Biopharma2026-05-07 12:30 EST

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-03-19 12:30 EST

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-03-03 13:30 EST

Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions

Stock data

Close
16.92 USD
Market cap
803.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States